
CareDx, Inc
CDNANASDAQHealthcareMedical - Diagnostics & Research
Previous close
$48.61
+$1.62 · +3.45%
CDNA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
8
Overpriced
Momentum
70
Gaining
Sentiment
57
Mixed
Risk resilience
44
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- John Walter Hanna Jr.
- Listed since
- Jul 17, 2014
- Employees
- 763
Market position
Day range
Current $48.61
52-week range
Current $48.61
- Open
- $46.99
- Previous close
- $46.99
- Volume
- 1.16M
- 1.19× average
- Average volume
- 978.83K
- Average daily volume
- Market cap
- 2.51B USD
- Beta
- 2.42
- Market reference 1
- 50-day average
- $35.671
- +36.27% above average
- 200-day average
- $23.3534
- +108.15% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 964.7M USD
- P/E (TTM)
- 22.59×
- P/B (TTM)
- 5.88×
- P/S (TTM)
- 5.49×
- EV / EBITDA
- -207.24×
- Earnings yield
- -2.13%
- Free cash flow yield
- 3.60%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 70.58%
- Operating margin
- -0.92%
- Net margin
- 24.23%
- Return on equity
- -7.05%
- Return on assets
- -5.17%
- Return on invested capital
- -7.60%
Financial health
- Debt / equity
- 0.05×
- Current ratio
- 2.86×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 379.81M USD | 333.79M USD | 280.32M USD | 321.79M USD | 296.4M USD |
| Cost of goods sold | 123.24M USD | 109.63M USD | 102M USD | 112.21M USD | 97.39M USD |
| Gross profit | 256.57M USD | 224.16M USD | 178.33M USD | 209.58M USD | 199.01M USD |
| Research and development | 71.43M USD | 72.41M USD | 81.87M USD | 90.39M USD | 76.53M USD |
| Selling, general, and administrative | 210.21M USD | 205.5M USD | 201.2M USD | 196.42M USD | 152.21M USD |
| Operating expenses | 281.64M USD | 183.39M USD | 381.69M USD | 286.81M USD | 228.73M USD |
| Interest income | 9.17M USD | 11.77M USD | 11.87M USD | 3.76M USD | 160K USD |
| Depreciation and amortization | 20.42M USD | 19.76M USD | 19.82M USD | 16.01M USD | 11.89M USD |
| Operating income | −25.07M USD | 40.77M USD | −203.36M USD | −77.23M USD | −29.73M USD |
| Net income | −21.35M USD | 52.55M USD | −190.28M USD | −76.61M USD | −30.66M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 91%
- 10 beats, 1 miss, 0 met estimates
- Average EPS surprise
- +151.88%
- 11 comparable reports
- Latest EPS result
- 0.37
- Estimate 0.23 · Beat by 59.41%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$56.67
16.58% upsideRating distribution
13 ratingsRecent analyst actions
CDNA news
CDNA peers
ETFs holding CDNA
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG68.16M3.58%1.56B USD0.75%$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI68.12M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM62.07M0.08%81.62B USD0.19%$299.96+0.77%
State Street SPDR S&P Biotech ETFXBI56.39M0.49%11.39B USD0.35%$165.73+1.44%
Vanguard Extended Market ETFVXF26.05M0.03%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO22.25M0.15%15.16B USD0.24%$387.37+1.24%
Invesco Biotechnology & Genome ETFPBE19.98M5.02%401.81M USD0.58%$97.59+1.07%
iShares Biotechnology ETFIBB16.41M0.15%10.75B USD0.44%$213.56+1.29%
ARK Genomic Revolution ETFARKG- Market value
- 68.16M
- Weight
- 3.58%
- AUM
- 1.56B USD
- Expense ratio
- 0.75%
- Price / 1D
- $49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 68.12M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 62.07M
- Weight
- 0.08%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
State Street SPDR S&P Biotech ETFXBI- Market value
- 56.39M
- Weight
- 0.49%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Extended Market ETFVXF- Market value
- 26.05M
- Weight
- 0.03%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 22.25M
- Weight
- 0.15%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Invesco Biotechnology & Genome ETFPBE- Market value
- 19.98M
- Weight
- 5.02%
- AUM
- 401.81M USD
- Expense ratio
- 0.58%
- Price / 1D
- $97.59+1.07%
iShares Biotechnology ETFIBB- Market value
- 16.41M
- Weight
- 0.15%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Continue in GoAI
Research CDNAresearch.disclaimer











